| Literature DB >> 15673319 |
Kwok Hong Chu1, Wai Kay Tsang, Colin S Tang, Man Fai Lam, Fernand M Lai, Ka Fai To, Ka Shun Fung, Hon Lok Tang, Wing Wa Yan, Hilda W H Chan, Thomas S T Lai, Kwok Lung Tong, Kar Neng Lai.
Abstract
BACKGROUND: Severe acute respiratory syndrome (SARS) is a newly emerged infection from a novel coronavirus (SARS-CoV). Apart from fever and respiratory complications, acute renal impairment has been observed in some patients with SARS. Herein, we describe the clinical, pathologic, and laboratory features of the acute renal impairment complicating this new viral infection.Entities:
Mesh:
Substances:
Year: 2005 PMID: 15673319 PMCID: PMC7112337 DOI: 10.1111/j.1523-1755.2005.67130.x
Source DB: PubMed Journal: Kidney Int ISSN: 0085-2538 Impact factor: 10.612
Various laboratory and clinical parameters of patients with acute renal impairment and normal kidney function
| Variable | Renal impairment ( | Normal renal function ( | |
|---|---|---|---|
| Age | 53.5 (34–77) | 38.0 (18–96) | <0.001 |
| Systolic blood pressure | 130.5 (105–200) | 125.0 (96–210) | 0.013 |
| Diastolic blood pressure | 70.0 (54–100) | 70.0 (40–109) | 0.942 |
| Hemoglobin g/dL | 14.0 (8.4–16.9) | 13.2 (7.6–18) | 0.035 |
| White blood cells (×109/L) | 6.5 (1.8–16.3) | 5.30 (1.55–27.3) | 0.005 |
| Neutrophil (×109/L) | 5.00 (0.8–15.5) | 3.90 (0.7–26.3) | 0.004 |
| Lymphocyte (×109/L) | 0.80 (0.3–2.8) | 0.80 (0.2–3.1) | 0.556 |
| Platelet (×109/L) | 151.0 (79–285) | 163.0 (41–893) | 0.671 |
| Prothrombin time | 11.9 (10.2–14.1) | 12.0 (0.4–120) | 0.391 |
| Activated partial thromboplastin time | 33.2 (23.3–87) | 32.2 (14–120) | 0.092 |
| Plasma sodium | 132.0 (126–140) | 134.0 (121–144) | 0.001 |
| Plasma potassium | 3.7 (2.8–6.1) | 3.6 (2.2–8.1) | 0.634 |
| Plasma urea | 4.6 (1.8–16) | 3.4 (0.3–18.6) | <0.001 |
| Plasma creatinine | 93.5 (48–128) | 70.0 (40–123) | <0.001 |
| Plasma albumin | 34.0 (23–44) | 38.0 (20–50) | <0.001 |
| Plasma alanine aminotranferase | 49.0 (12–193) | 26.0 (3–587) | 0.001 |
| Plasma lactate dehydrogenase | 311.0 (148–990) | 218.5 (30–1669) | <0.001 |
| Nadir hemoglobin | 8.7 (3.4–15.5) | 11.3 (3.9–15.8) | <0.001 |
| Nadir white blood cells (×109/L) | 5.35 (1.8–10.5) | 4.00 (0.8–20.5) | 0.003 |
| Nadir lymphocyte (×109/L) | 0.30 (0.1–0.7) | 0.40 (0–7.3) | <0.001 |
| Plasma peak creatine phosphokinase | 222.0 (26–22974) | 96.0 (11–7154) | <0.001 |
| Symptomatic days before admission | 1.0 (1–3) | 3.0 (1–15) | 0.071 |
Measurement at first admission.
Figure 1Serial measurement of plasma creatinine (expressed as median) of these 36 severe acute respiratory syndrome (SARS) patients complicated with acute renal failure (ARF).
Figure 2Plasma creatinine concentrations. (A) The least squares mean plasma creatinine concentration over time for alive patients (N = 3) and deceased patients (N = 33) deducted from polynomial equations of mixed linear model. (B) The least squares mean plasma creatinine concentration deducted from polynomial equations of mixed linear model for patients who died within 15 days (N = 12), within 15 to 30 days (N = 19), and after 30 days (N = 2). FU is the duration of hospitalization.
Risk factors of mortality in severe acute respiratory syndrome (SARS) by univariate analysis
| Relative risk (99% CI) | ||
|---|---|---|
| Use of inotropes | 15.77 (7.539–32.99) | <0.001 |
| Acute renal impairment | 16.91 (8.368–34.16) | <0.001 |
| Acute respiratory distress syndrome | 10.28 (4.854–21.77) | <0.001 |
| Systolic blood pressure | 1.014 (0.997–1.031) | 0.032 |
| White blood cells | 1.066 (0.988–1.150) | 0.029 |
| Lymphocyte count | 0.529 (0.209–1.339) | 0.077 |
| Nadir white blood cells | 1.160 (1.057–1.272) | <0.001 |
| Nadir lymphocyte count | 0.016 (0.001–0.217) | <0.001 |
| Plasma albumin on admission | 0.890 (0.841–0.942) | <0.001 |
| Peak plasma creatine phosphokinase > 1500 | 6.689 (1.699–26.34) | <0.001 |
| Plasma alanine aminotransferase on admission | 1.005 (1.001–1.009) | 0.004 |
| Age | 1.049 (1.029–1.068) | <0.001 |
Patients with creatine phosphokinase less than 1500 serve as the reference group.
Independent risk factor predicting mortality in severe acute respiratory syndrome (SARS) by multivariate analysis
| Adjusted relative risk (99% CI) | ||
|---|---|---|
| Acute renal impairment | 4.057 (1.461–11.27) | <0.001 |
| Acute respiratory distress syndrome | 3.286 (1.141–9.463) | 0.004 |
| Age | 1.033 (1.008–1.058) | 0.001 |
| Plasma albumin on admission | 0.936 (0.876–0.999) | 0.009 |
Risk factors of the development of acute renal impairment in severe acute respiratory syndrome (SARS) by univariate analysis
| Relative risk (99% CI) | ||
|---|---|---|
| Use of inotropes | 124.2 (19.01–811.4) | <0.001 |
| Acute respiratory distress syndrome | 46.60 (9.800–221.6) | <0.001 |
| Systolic blood pressure | 1.017 (0.997–1.038) | 0.032 |
| White blood cells | 1.047 (0.943–1.164) | 0.257 |
| Lymphocyte count | 0.717 (0.233–2.205) | 0.446 |
| Nadir white blood cells | 1.115 (0.980–1.267) | 0.029 |
| Nadir lymphocyte count | 0.039 (0.002–0.812) | 0.006 |
| Plasma albumin on admission | 0.904 (0.842–0.971) | <0.001 |
| Peak plasma creatine phosphokinase > 1500 | 12.65 (3.039–52.64) | <0.001 |
| Plasma alanine transferase on admission | 1.005 (1.001–1.010) | 0.004 |
| Age | 1.044 (1.019–1.069) | <0.001 |
Patients with creatine phosphokinase less than 1500 serve as the reference group.
Independent risk factor predicting the development of acute renal impairment in severe acute respiratory syndrome (SARS) by multivariate analysis
| Adjusted relative risk (99% CI) | ||
|---|---|---|
| Acute respiratory distress syndrome | 37.91 (7.969–180.4) | <0.001 |
| Age | 1.037 (1.007–1.067) | 0.001 |
Clinical and pathologic findings of seven severe acute respiratory syndrome (SARS) patients undergoing postmortem examination
| Case number | Gender/age | SARS confirmed by polymerase chain reaction | Kidney confirmed by light microscopy | Benign nephrosclerosis | Viral particles by electron microscopy | Autolysis | Plasma creatinine at presentation | Plasma creatinine at the time of death | Postmortem cause of death |
|---|---|---|---|---|---|---|---|---|---|
| 1 | M/69 | Yes | Moderate acute tubular necrosis | + | Not detected | Yes | 100 | 258 | Diffuse alveolar damage |
| 2 | M/64 | Yes | Moderate acute tubular necrosis | + | Not detected | Yes | 88 | 209 | Diffuse alveolar damage |
| 3 | M/76 | Yes | Severe acute tubular necrosis | + | Not detected | Yes | 153 | 179 | Diffuse alveolar damage |
| 4 | F/81 | Yes | Mild acute tubular necrosis | + | Not detected | Minimal | 107 | 131 | Diffuse alveolar damage |
| 5 | M/44 | Yes | Severe acute tubular necrosis | - | not detected | yes | 107 | 315 | Diffuse alveolar damage |
| 6 | M/79 | Yes | Moderate acute tubular necrosis | + | not detected | yes | 179 | 238 | Diffuse alveolar damage |
| 7 | F/91 | Yes | Minimal | + | not detected | yes | 75 | 97 | Diffuse alveolar damage |
Heavy abnormal myeloid infiltrate in the kidney (the patient had history of myelodysplastic syndrome).